US 11,793,805 B2
Methods for treating antipsychotic-induced weight gain
Daniel R. Deaver, Wilmington, NC (US); and Mark Todtenkopf, Franklin, MA (US)
Assigned to Alkermes Pharma Ireland Limited, Dublin (IE)
Filed by Alkermes Pharma Ireland Limited, Dublin (IE)
Filed on Oct. 20, 2021, as Appl. No. 17/505,896.
Application 16/390,531 is a division of application No. 15/923,084, filed on Mar. 16, 2018, granted, now 10,300,054, issued on May 28, 2019.
Application 17/505,896 is a continuation of application No. 16/899,708, filed on Jun. 12, 2020, granted, now 11,185,541.
Application 16/899,708 is a continuation of application No. 16/390,531, filed on Apr. 22, 2019, granted, now 10,716,785, issued on Jul. 21, 2020.
Application 15/923,084 is a continuation of application No. 15/342,263, filed on Nov. 3, 2016, granted, now 9,943,514, issued on Apr. 17, 2018.
Application 15/342,263 is a continuation of application No. 14/813,260, filed on Jul. 30, 2015, granted, now 9,517,235, issued on Dec. 13, 2016.
Application 14/813,260 is a continuation of application No. 14/297,171, filed on Jun. 5, 2014, granted, now 9,126,977, issued on Sep. 8, 2015.
Application 14/297,171 is a continuation of application No. 13/215,718, filed on Aug. 23, 2011, granted, now 8,778,960, issued on Jul. 15, 2014.
Claims priority of provisional application 61/376,120, filed on Aug. 23, 2010.
Prior Publication US 2022/0280502 A1, Sep. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/485 (2006.01); A61K 31/439 (2006.01); A61K 31/496 (2006.01); A61K 31/519 (2006.01); A61K 31/5513 (2006.01); A61K 31/554 (2006.01); C07D 221/28 (2006.01); C07D 405/06 (2006.01); A61K 9/20 (2006.01); A61K 31/551 (2006.01)
CPC A61K 31/485 (2013.01) [A61K 9/20 (2013.01); A61K 31/439 (2013.01); A61K 31/496 (2013.01); A61K 31/519 (2013.01); A61K 31/551 (2013.01); A61K 31/554 (2013.01); A61K 31/5513 (2013.01); C07D 221/28 (2013.01); C07D 405/06 (2013.01)] 9 Claims
 
1. A method of treating schizophrenia, in a patient in need thereof, where the patient has previously experienced significant weight gain induced by olanzapine treatment alone, comprising administering to the patient a daily dose of a pharmaceutical composition comprising:
olanzapine or a pharmaceutically acceptable salt thereof; and
10 mg of a compound having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.